Cancer Monoclonal Antibodies Market - Forecast(2022 - 2027)

Report Code: HCR 12157 Report Format: PDF + Excel

Cancer Monoclonal Antibodies Market Overview

The Cancer Monoclonal Antibodies Market size is forecast to reach $72.6 billion by 2026, growing at a CAGR of 10.0 % during the forecast period 2021-2026. Monoclonal antibodies are created by cloning a specific type of white blood cell. These are laboratory-created molecules that act as replacement antibodies, restoring and enhancing the immune system's attack on cancer cells. Monoclonal antibodies attach to proteins on cancer cells surfaces, triggering an immune response. Bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), panitumumab (Vectibix), and others are some of the therapies used in the treatment of monoclonal antibodies. In the flow-through mode, anion exchange chromatography (AEX) is a frequently used purification method for removing process/product-related contaminants and exogenous/endogenous viruses from monoclonal antibodies (mAbs). Increasing preference for monoclonal antibodies to target cancer because of their specificity and technological advancements in genetic sequencing are the major factors driving the growth of the market. The growing prevalence of different types of cancer and increasing investment in the R&D by the government bodies is set to further enhance the overall market developments of the Cancer Monoclonal Antibodies Market for the period 2021-2026.

Report Coverage

The report: “Cancer Monoclonal Antibodies Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Cancer Monoclonal Antibodies Market.
By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies.
By Therapy: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others.
By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (Middle East, and Africa).

Key Takeaways

  • North America dominated the Cancer Monoclonal Antibodies Market in 2020 owing to the rising prevalence of cancer cases and increasing government spending for cancer diseases research and development. The Cancer Monoclonal Antibodies Market scope for different regions will be provided in the final report.
  • Increasing preference towards the specificity of monoclonal antibodies to target cancer and growing investment in research and development activities of genomic studies are likely to aid the market growth of the Cancer Monoclonal Antibodies Market report.
  • Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be the Cancer Monoclonal Antibodies Market report.
  • Stringent government regulations and high costs involved in the development of monoclonal antibodies are poised to create the hurdles for the Cancer Monoclonal Antibodies Market.

Cancer Monoclonal Antibodies Market Revenue Share, By Geography, 2020(%)

For More Details on This Report - Request for Sample

Cancer Monoclonal Antibodies Market Analysis – By Type

Murine Antibodies held the largest share in the Cancer Monoclonal Antibodies Market in 2020 and is estimated to grow at a CAGR of 10.4% during the forecast period 2021-2026. This is owing to the factor as it is important in the development of modern antibody manufacturing processes and the expansion of immunoglobin's application potential. It also extends the half-life of monoclonal antibodies (mAbs) in the blood, which increases the demand for these antibodies. Humanized Antibodies is estimated to register the higher CAGR over the period 2021-2026 owing to its properties such as the immunogenicity of the mAb are reduced and the incorporation of advanced technologies such as phase or yeast display.

Cancer Monoclonal Antibodies Market Analysis – By Applications

Breast Cancer held the largest share in the Cancer Monoclonal Antibodies Market in 2020 and is estimated to grow at a CAGR 10.9% during the forecast period 2021-2026. This is owing to factors such as increased exposure to harmful radiation, lack of physical activity, an increase in the adoption of an unhealthy lifestyle, expanding government initiatives towards awareness regarding breast cancer, and an increase in the female geriatric population. According to World Health Organization (WHO), 2.3 million women were diagnosed with breast cancer and 6, 85,000 deaths were recorded globally in the year 2020. Breast cancer had been diagnosed in 7.8 million women in the previous five years as of the end of 2020, making it the most common cancer in the world. This segment is also estimated to register a higher CAGR over the period 2021-2026.

Cancer Monoclonal Antibodies Market Analysis – By Geography

North America dominated the Cancer Monoclonal Antibodies Market with a major share of 37.9% in 2020. This is attributed to the technological advancements in genetic sequencing and target gene selection increased investment by major players and an increase in the female elderly population. Increased government investments in overall R&D of monoclonal antibody therapy, as well as an increase in the number of product approvals, are also increasing the growth of the market in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the increasing awareness regarding the advanced Cancer Monoclonal Antibodies and emerging demand for novel cancer therapies in this region.

Cancer Monoclonal Antibodies Market Drivers

Increasing Incidences of Cancer is driving the demand for Cancer Monoclonal Antibodies

Increasing incidences of cancer are increasing the growth of the Cancer Monoclonal Antibodies Market. According to the American Cancer Society, 1.7 million new cancer cases and 0.6 million cancer deaths occurred in the United States in 2019. Lung, prostate, bowel, and female breast cancer are the four most frequent kinds of cancer worldwide, accounting for 43 percent of all new cancer cases. As a result, rising cancer incidence rates around the world are expected to drive demand for cancer monoclonal antibodies. In Non-targeted therapies that include chemotherapy, monoclonal antibodies tend to reduce the side effects of the patient’s body. It is also used for treating inflammatory and autoimmune diseases. The market is expected to grow as oncologists and medical practitioners adopt more cost-effective monoclonal antibodies for cancer, as well as demand for tailored treatments and increased cancer research and development which are also helping in the growth of the market during the forecast period 2021-2026.

Increasing Investment in Research & Development Activities

Increasing investment in research & development activities is increasing the growth of the Cancer Monoclonal Antibodies Market. Research & development activities helps to accumulate knowledge about the process that is involved in cancer growth, onset and spread in the body. It also leads to more effective and targeted treatments and prevention strategies.  Thus, increasing the growth of the market during the forecast period 2021-2026.

Cancer Monoclonal Antibodies Market Challenges

Stringent Regulations and Improper Reimbursement is restraining the growth of Cancer Monoclonal Antibody

Some of the factors that are set to impede the growth of the Cancer Monoclonal Antibodies Market are government restrictions for product approval which are strict, and the costs of generating monoclonal antibodies utilizing modern techniques are costly. High research costs associated with the advanced techniques for the development of Cancer Monoclonal Antibodies are also set to hinder the growth of the market during the forecast period 2021-2026.

Cancer Monoclonal Antibodies Market Landscape

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Cancer Monoclonal Antibodies Market. In 2020, the Cancer Monoclonal Antibodies Market share is consolidated by the top ten players present in the market. The Cancer Monoclonal Antibodies Market, the top 10 companies are 

  • Amgen, Bristol Myers Squibb
  • Eli Lilly and Company 
  • F.Hoffman –La Roche Ltd.
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Novartis AG.
  • Merck & Co.
  • Genmab AS
  • Spectrum Pharmaceuticals among others.

Relevant Titles:

Monoclonal Antibodies Market - Forecast(2021 - 2026)
Report Code: HCR 0320

Cancer Biomarkers Market - Industry Analysis, Market Size, Share, Trends, Growth And Forecast 2021 - 2026
Report Code: HCR 0194 

For more Lifesciences and Healthcare related reports, please click here

1. Cancer Monoclonal Antibodies Market- Overview
    1.1 Definitions and Scope
2. Cancer Monoclonal Antibodies Market- Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Type
    2.3 Key trends by Therapy
    2.4 Key trends by Application
    2.5 Key trends by Geography
3. Cancer Monoclonal Antibodies Market– Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis-Average Selling Price
4. Cancer Monoclonal Antibodies Market- Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Cancer Monoclonal Antibodies Market– Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Cancer Monoclonal Antibodies Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Cancer Monoclonal Antibodies Market– Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Cancer Monoclonal Antibodies Market – By Type (Market Size –$Million/$Billion)
    8.1 Murine Antibodies
    8.2 Chimeric Antibodies
    8.3 Humanized Antibodies
9. Cancer Monoclonal Antibodies Market – By Therapy (Market Size –$Million/$Billion)
    9.1 Bevacizumab (Avastin)
    9.2 Rituximab (Rituxan)
    9.3 Trastuzumab (Herceptin)
    9.4 Cetuximab (Erbitux)
    9.5 Panitumumab (Vectibix)
    9.6 Others
10. Cancer Monoclonal Antibodies Market – By Application (Market Size –$Million/$Billion)
    10.1 Breast Cancer
    10.2 Blood Cancer
    10.3 Liver Cancer
    10.4 Brain Cancer
    10.5 Colorectal Cancer
    10.6 Others
11. Cancer Monoclonal Antibodies Market- By Geography(Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Cancer Monoclonal Antibodies Market- Entropy
13. Cancer Monoclonal Antibodies Market– Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Competition Matrix
        13.1.5 Best Practices for Companies
14. Cancer Monoclonal Antibodies Market– Key Company List by Country Premium Premium
15. Cancer Monoclonal Antibodies Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global MARKET SEGMENTATION Market 2019-2024 ($M)
1.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Global Industry Research
1.1.1 Murine Antibodies Market 2019-2024 ($M)
1.1.2 Chimeric Antibodies Market 2019-2024 ($M)
1.1.3 Humanized Antibodies Market 2019-2024 ($M)
1.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Global Industry Research
1.2.1 Bevacizumab Market 2019-2024 ($M)
1.2.2 Rituximab Market 2019-2024 ($M)
1.2.3 Trastuzumab Market 2019-2024 ($M)
1.2.4 Cetuximab Market 2019-2024 ($M)
1.2.5 Panitumumab Market 2019-2024 ($M)
1.2.7 Breast Cancer Market 2019-2024 ($M)
1.2.8 Blood Cancer Market 2019-2024 ($M)
1.2.9 Liver Cancer Market 2019-2024 ($M)
1.2.10 Brain Cancer Market 2019-2024 ($M)
1.2.11 Colorectal Cancer Market 2019-2024 ($M)
2.Global COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
3.Global MARKET SEGMENTATION Market 2019-2024 (Volume/Units)
3.1 Types of Monoclonal Antibody Market 2019-2024 (Volume/Units) - Global Industry Research
3.1.1 Murine Antibodies Market 2019-2024 (Volume/Units)
3.1.2 Chimeric Antibodies Market 2019-2024 (Volume/Units)
3.1.3 Humanized Antibodies Market 2019-2024 (Volume/Units)
3.2 Monoclonal Antibody Therapies Market 2019-2024 (Volume/Units) - Global Industry Research
3.2.1 Bevacizumab Market 2019-2024 (Volume/Units)
3.2.2 Rituximab Market 2019-2024 (Volume/Units)
3.2.3 Trastuzumab Market 2019-2024 (Volume/Units)
3.2.4 Cetuximab Market 2019-2024 (Volume/Units)
3.2.5 Panitumumab Market 2019-2024 (Volume/Units)
3.2.7 Breast Cancer Market 2019-2024 (Volume/Units)
3.2.8 Blood Cancer Market 2019-2024 (Volume/Units)
3.2.9 Liver Cancer Market 2019-2024 (Volume/Units)
3.2.10 Brain Cancer Market 2019-2024 (Volume/Units)
3.2.11 Colorectal Cancer Market 2019-2024 (Volume/Units)
4.Global COMPETITIVE LANDSCAPE Market 2019-2024 (Volume/Units)
5.North America MARKET SEGMENTATION Market 2019-2024 ($M)
5.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
5.1.1 Murine Antibodies Market 2019-2024 ($M)
5.1.2 Chimeric Antibodies Market 2019-2024 ($M)
5.1.3 Humanized Antibodies Market 2019-2024 ($M)
5.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
5.2.1 Bevacizumab Market 2019-2024 ($M)
5.2.2 Rituximab Market 2019-2024 ($M)
5.2.3 Trastuzumab Market 2019-2024 ($M)
5.2.4 Cetuximab Market 2019-2024 ($M)
5.2.5 Panitumumab Market 2019-2024 ($M)
5.2.7 Breast Cancer Market 2019-2024 ($M)
5.2.8 Blood Cancer Market 2019-2024 ($M)
5.2.9 Liver Cancer Market 2019-2024 ($M)
5.2.10 Brain Cancer Market 2019-2024 ($M)
5.2.11 Colorectal Cancer Market 2019-2024 ($M)
6.North America COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
7.South America MARKET SEGMENTATION Market 2019-2024 ($M)
7.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
7.1.1 Murine Antibodies Market 2019-2024 ($M)
7.1.2 Chimeric Antibodies Market 2019-2024 ($M)
7.1.3 Humanized Antibodies Market 2019-2024 ($M)
7.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
7.2.1 Bevacizumab Market 2019-2024 ($M)
7.2.2 Rituximab Market 2019-2024 ($M)
7.2.3 Trastuzumab Market 2019-2024 ($M)
7.2.4 Cetuximab Market 2019-2024 ($M)
7.2.5 Panitumumab Market 2019-2024 ($M)
7.2.7 Breast Cancer Market 2019-2024 ($M)
7.2.8 Blood Cancer Market 2019-2024 ($M)
7.2.9 Liver Cancer Market 2019-2024 ($M)
7.2.10 Brain Cancer Market 2019-2024 ($M)
7.2.11 Colorectal Cancer Market 2019-2024 ($M)
8.South America COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
9.Europe MARKET SEGMENTATION Market 2019-2024 ($M)
9.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
9.1.1 Murine Antibodies Market 2019-2024 ($M)
9.1.2 Chimeric Antibodies Market 2019-2024 ($M)
9.1.3 Humanized Antibodies Market 2019-2024 ($M)
9.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
9.2.1 Bevacizumab Market 2019-2024 ($M)
9.2.2 Rituximab Market 2019-2024 ($M)
9.2.3 Trastuzumab Market 2019-2024 ($M)
9.2.4 Cetuximab Market 2019-2024 ($M)
9.2.5 Panitumumab Market 2019-2024 ($M)
9.2.7 Breast Cancer Market 2019-2024 ($M)
9.2.8 Blood Cancer Market 2019-2024 ($M)
9.2.9 Liver Cancer Market 2019-2024 ($M)
9.2.10 Brain Cancer Market 2019-2024 ($M)
9.2.11 Colorectal Cancer Market 2019-2024 ($M)
10.Europe COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
11.APAC MARKET SEGMENTATION Market 2019-2024 ($M)
11.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
11.1.1 Murine Antibodies Market 2019-2024 ($M)
11.1.2 Chimeric Antibodies Market 2019-2024 ($M)
11.1.3 Humanized Antibodies Market 2019-2024 ($M)
11.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
11.2.1 Bevacizumab Market 2019-2024 ($M)
11.2.2 Rituximab Market 2019-2024 ($M)
11.2.3 Trastuzumab Market 2019-2024 ($M)
11.2.4 Cetuximab Market 2019-2024 ($M)
11.2.5 Panitumumab Market 2019-2024 ($M)
11.2.7 Breast Cancer Market 2019-2024 ($M)
11.2.8 Blood Cancer Market 2019-2024 ($M)
11.2.9 Liver Cancer Market 2019-2024 ($M)
11.2.10 Brain Cancer Market 2019-2024 ($M)
11.2.11 Colorectal Cancer Market 2019-2024 ($M)
12.APAC COMPETITIVE LANDSCAPE Market 2019-2024 ($M)
13.MENA MARKET SEGMENTATION Market 2019-2024 ($M)
13.1 Types of Monoclonal Antibody Market 2019-2024 ($M) - Regional Industry Research
13.1.1 Murine Antibodies Market 2019-2024 ($M)
13.1.2 Chimeric Antibodies Market 2019-2024 ($M)
13.1.3 Humanized Antibodies Market 2019-2024 ($M)
13.2 Monoclonal Antibody Therapies Market 2019-2024 ($M) - Regional Industry Research
13.2.1 Bevacizumab Market 2019-2024 ($M)
13.2.2 Rituximab Market 2019-2024 ($M)
13.2.3 Trastuzumab Market 2019-2024 ($M)
13.2.4 Cetuximab Market 2019-2024 ($M)
13.2.5 Panitumumab Market 2019-2024 ($M)
13.2.7 Breast Cancer Market 2019-2024 ($M)
13.2.8 Blood Cancer Market 2019-2024 ($M)
13.2.9 Liver Cancer Market 2019-2024 ($M)
13.2.10 Brain Cancer Market 2019-2024 ($M)
13.2.11 Colorectal Cancer Market 2019-2024 ($M)
14.MENA COMPETITIVE LANDSCAPE Market 2019-2024 ($M)

LIST OF FIGURES

1.US Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
2.Canada Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
3.Mexico Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
4.Brazil Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
5.Argentina Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
6.Peru Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
7.Colombia Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
8.Chile Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
9.Rest of South America Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
10.UK Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
11.Germany Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
12.France Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
13.Italy Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
14.Spain Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
15.Rest of Europe Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
16.China Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
17.India Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
18.Japan Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
19.South Korea Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
20.South Africa Cancer Monoclonal Antibodies Market Revenue, 2019-2024 ($M)
21.North America Cancer Monoclonal Antibodies By Application
22.South America Cancer Monoclonal Antibodies By Application
23.Europe Cancer Monoclonal Antibodies By Application
24.APAC Cancer Monoclonal Antibodies By Application
25.MENA Cancer Monoclonal Antibodies By Application